Plain-English translation of NCT07262619 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing an experimental medication called to treat advanced solid tumors that have spread or cannot be surgically removed. The study will test the medication both on its own and in combination with pembrolizumab, a type of immunotherapy that helps your immune system fight cancer. Researchers want to find the right dose and learn whether this treatment works for people whose cancers have certain genetic features (called MSI-H or dMMR) or who haven't responded to other treatments.
Many people with advanced cancers stop responding to standard treatments, and doctors need new options. This medication targets a protein involved in cancer cell repair, and early research suggests it may work especially well for cancers with specific genetic changes or when combined with immunotherapy.
You likely qualify if…
You likely don't qualify if…
The study has three parts. In Part 1A, some participants will receive the medication alone at increasing doses to find the safest dose. In Part 1B, other participants will receive the medication combined with pembrolizumab, also at increasing doses. In Part 2, participants will be randomly assigned to receive the medication at one of two selected doses identified from Part 1A. You will have regular visits to the study center for blood tests, imaging scans, and physical exams to monitor how well the treatment is working and check for side effects.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States